Pressmeddelande -
Christian W. Jansson is proposed as the new Chairman of the Board of Enzymatica
Christian W. Jansson, former President and CEO of KappAhl – a leading Swedish clothes retailer – has been proposed as the new Chairman of the Board of Enzymatica. The election of the Board Chairman will be dealt with at the AGM on 6th of May. Christian W. Jansson would replace Åke Larsson, who has not sought reelection.
“We are very gratified that Christian W. Jansson has accepted the proposal to be Board Chairman. His experience from the retail trade and publicly traded companies will be valuable now that Enzymatica is commercializing its operations via a broad-based market introduction of ColdZyme® Mouth Spray and other products,” says Michael Edelborg Christensen, CEO at Enzymatica.
“Enzymatica is a highly exciting company which is now launching innovative products designed to prevent and treat a number of our most common illnesses, such as colds. I believe that that the company has considerable potential to succeed in building up robust operations both in Sweden and internationally,” notes Christian W. Jansson.
Christian W. Jansson is Chairman of the Board of Svensk Handel (Swedish Trade Federation) and Apoteket AB (major Swedish pharmacy chain) and is a member of the boards of Svenskt Näringsliv (Confederation of Swedish Enterprise), Bong AB, KappAhl AB, Europris AS and others. Christian W. Jansson has also been active in the Bonnier Dental Group, which is responsible both for global and European operations.
For more information on Enzymatica, contact:
Michael Edelborg Christensen, CEO at Enzymatica AB (publ), 0768-14 41 66,
michael.christensen@enzymatica.se
Ämnen
- Sjukdomar
Kategorier
- annual general meeting
- chairman of the board
- enzymatica
About
Enzymatica AB (publ)
Enzymatica
AB (publ) is a publicly traded biotechnology company focusing on research,
development and sales of medical devices based on patented enzyme technology.
Enzymatica utilizes a marine enzyme, a cold-adapted trypsine derived from
deep-sea cod. The enzyme has a unique property that makes it super-active at
about 37° C, making it superior in breaking down illness-related proteins,
counteracting viral and bacterial infections and promoting healing processes.
Enzymatica currently has two registered medical devices, PeriZyme chewing gum
against diseases and ColdZyme CE oral spray for colds recently launched in
pharmacies throughout the country.
About
Enzymatica on the web
Enzymatica’s press room »
Enzymatica’s
website »
Enzymatica on
LinkedIn »
Enzymatica on
Twitter »
For Investors »
ColdZyme website »
ColdZyme on Facebook »
